Leading change in epilepsy care
Epilepsy is one of the most common serious neurological conditions in the world. Around 65 million people have epilepsy worldwide. Disease management has improved over several decades but there is still a lot of work to do.
While about half of those diagnosed with epilepsy become seizure free with their first anti-epileptic drug, one third of people with epilepsy live with uncontrolled seizures because none of the available treatments works for them.
At UCB, we are committed to leading the way to better care for people with epilepsy. Our scientists are dedicated to expanding the treatment options for people with epilepsy, working to identify new therapies that can quickly control seizures.
As an industry leader in the field, UCB is delighted to join experts in Vienna this week (26-30 August) to discuss the latest thinking in epilepsy at the 13th European Congress on Epileptology.
This biennial meeting, which is a collaboration of the International Bureau for Epilepsy (IBE) and the International League Against Epilepsy (ILAE), is a unique opportunity for face-to-face interaction with the finest minds in the field. It offers insights into the latest research and allows us to update the community on data from our epilepsy research projects.
One of our data submissions has been selected for an oral presentation, reinforcing our position on the cutting edge of epileptology. We will share new results that illustrate how our efforts, in collaboration with Yale University, can translate into new treatment options for people living with the disease.
We will continue to partner with leading researchers in pursuit of our shared goal: improving epilepsy care for the millions of individuals and families affected.